Clinical Trials
7 trialsNCT05563844 2026-02-04
Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 2 Active not recruiting
NCT07288879 2026-01-08
DALY II Japan
Miltenyi Biomedicine GmbH
Phase 2 Recruiting
NCT03003520 2023-05-22
A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma
Celgene
Phase 2 Completed
NCT00099255 2014-12-18
Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma
Seagen Inc.
Phase 2 Completed
NCT01118845 2013-07-04
Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma
SymBio Pharmaceuticals
Phase 2 Completed
NCT00298467 2010-04-26
MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma
Bristol-Myers Squibb
Phase 2 Withdrawn
NCT00002003 2005-06-24
Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients With HIV Associated Large Cell and Immunoblastic Lymphomas
NIH AIDS Clinical Trials Information Service
Phase 2 Completed